Iovance Biotherapeutics, Inc. (0JDK.L)
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
$4.26-0.11%
StockGlow Score
Bearish
BearishBullish
1 year ago+64.2%
The outlook
Iovance Biotherapeutics, Inc. currently reads as bearish based on below its 50- & 200-day averages, 7% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Market cap
—
52-wk high
$18.31
52-wk low
$3.22
50-day avg
$11.04
200-day avg
$7.44
Trailing P/E
—